Organoids are simple tissue-engineered cell-based in vitro models that recapitulate many
aspects of the complex structure and function of the corresponding in vivo tissue. They can …

Patient‐derived cancer cells (PDCs) and patient‐derived xenografts (PDXs) are often used
as tumor models, but have many shortcomings. PDCs not only lack diversity in terms of cell …

The current drug development pipeline takes approximately fifteen years and $2.6 billion to
get a new drug to market. Typically, drugs are tested on two-dimensional (2D) cell cultures …

Decades of efforts in engineering in vitro cancer models have advanced drug discovery and
the insight into cancer biology. However, the establishment of preclinical models that enable …

Introduction We hypothesized that engineering a combined lymph node/melanoma organoid
from the same patient would allow tumor, stroma, and immune system to remain viable for …

The tumor microenvironment consists of diverse, complex etiological factors. The matrix
component of pancreatic ductal adenocarcinoma (PDAC) plays an important role not only in …

Organoids, and in particular patient-derived organoids, have emerged as crucial tools for
cancer research. Our organoid platform, which has supported patient-derived tumor …

The establishment of tumor microenvironment using biomimetic in vitro models that
recapitulate key tumor hallmarks including the tumor supporting extracellular matrix (ECM) is …

Human hematopoietic niches are complex specialized microenvironments that maintain and
regulate hematopoietic stem and progenitor cells (HSPC). Thus far, most of the studies …

Introduction Sarcoma clinical outcomes have been stagnant for decades due to
heterogeneity of primaries, lack of comprehensive preclinical models, and rarity of disease …